Ann Pediatr Endocrinol Metab.  2020 Sep;25(3):169-173. 10.6065/apem.1938176.088.

Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

• Lim KI
• Lee HS
• Hwang JS

• KMID: 2507559
• DOI: http://doi.org/10.6065/apem.1938176.088

Abstract

Purpose
Gonadotropin-releasing hormone agonist (GnRHa) is a safe and effective therapy used to treat central precocious puberty (CPP). Although most studies have reported no significant difference in body mass index (BMI) in girls during and after GnRHa therapy, few studies have investigated changes in BMI in boys with CPP. This study evaluated the effects of GnRHa therapy on BMI in boys with CPP.
Methods
This study included 75 boys with CPP at Ajou University Hospital between January 1, 2007 and December 31, 2016, who treated with leuprorelin acetate or triptorelin acetate every 4 weeks for at least 2 years. The subjects were divided into 3 groups according to BMI: normal weight, overweight, and obese. We analyzed the BMI standard deviation score (SDS) in each group before therapy and after 1 year and 2 years of therapy.
Results
Of the 75 boys, 37 were in the normal weight group, 21 were in the overweight group, and 17 were in the obese group. Magnetic resonance imaging that was performed before treatment showed abnormal findings in 9 boys. The mean BMI SDS for all participants at initiation was 1.0±0.8, and that in the normal weight, overweight, and obese groups was 0.3±0.4, 1.3±0.1, and 1.9±0.3, respectively. There were no significant differences in BMI SDS in any group after 1 or 2 years of treatment.
Conclusion
The BMI SDS in boys with CPP did not significantly change over 2 years of GnRHa therapy.

Keyword

Gonadotropin-releasing hormone; Central precocious puberty; Boy; Body mass index

Figure

• 

  Fig. 1. Changes in BMI SDS after 2 years of GnRHa therapy in participants with CPP. BMI, body mass index; SDS, standard deviation score; GnRHa, gonadotropin-releasing hormone agonist; CPP, central precocious puberty. Values are presented as mean. *P>0.05 compared with pretherapy values in all groups. †P>0.05 compared with pretherapy values in all groups.

• 

  Fig. 2. Changes in BMI SDS between the leuprolide acetate treatment group and the triptorelin acetate treatment group after 2 years of GnRHa therapy in participants with CPP. BMI, body mass index; SDS, standard deviation score; GnRHa, gonadotropin-releasing hormone agonist; CPP, central precocious puberty. Values are presented as mean. *P>0.05 compared with pretherapy values in all groups. †P>0.05 compared with pretherapy values in all groups.

• 

  Fig. 3. Changes in BMI SDS between the normal MRI group and the abnormal group after 2 years of GnRHa therapy in participants with CPP. BMI, body mass index; SDS, standard deviation score; MRI, magnetic resonance imaging; GnRHa, gonadotropin-releasing hormone agonist; CPP, central precocious puberty. Values are presented as mean. *P>0.05 compared with pretherapy values in all groups. †P>0.05 compared with pretherapy values in all groups.

Reference

References

1. Carel JC, Leger J. Precocious puberty. N Engl J Med. 2008; 358:2366–77.

2. Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, et al. Incidence and prevalence of central precocious puberty in korea: an epidemiologic study based on a national database. J Pediatr. 2019; 208:221–8.

3. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123:e752–62.

4. Antoniazzi F, Zamboni G. Central precocious puberty. Pediatr Drugs. 2004; 6:211–31.

5. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab. 1999; 84:4480–8.

6. Paterson W, McNeill E, Young D, Donaldson M. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf). 2004; 61:626–34.

7. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol. 2004; 150:533–7.

8. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84:4583–90.

9. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008; 93:190–5.

10. Arani KS, Heidari F. Gonadotropin-releasing hormone agonist therapy and obesity in girls. Int J Endocrinol Metab. 2015; 13:e23085.

11. Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012; 78:304–11.

12. Arcari A, Gryngarten M, Freire A, Ballerini M, Ropelato M, Bergadá I, et al. Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. Int J Pediatr Endocrinol. 2016; 2016:15.

13. Kim SW, Kim YB, Lee JE, Kim NR, Lee WK, Ku JK, et al. The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty. Ann Pediatr Endocrinol Metab. 2017; 22:95.

14. Arcari AJ, Freire AV, Escobar ME, Ballerini MG, Ropelato MG, Bergadá I, et al. One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty. J Pediatr Endocrinol Metab. 2019; 32:181–6.

15. Lee HS, Yoon JS, Roh JK, Hwang JS. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty. Endocrine. 2016; 54:497–503.

16. Feuillan PP, Jones JV, Barnes KM, Oerter-Klein K, Cutler Jr GB. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab. 2000; 85:4036–8.

17. Censani M, Feuer A, Orton S, Askin G, Vogiatzi M. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature. J Pediatr Endocrinol Metab. 2019; 32:1065–70.

18. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Dooms L, Malvaux P, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr. 1997; 86:808–15.

19. Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005; 116:1323–8.

20. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008; 51:1–25.

21. Greulich W, Pyle S. Radiologic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford (CA): Stanford University Press,;1999.